The Alliance for mRNA Medicines (AMM) is dedicated to advancing and advocating for an RNA platform approach to medicine, including protein replacements, gene editing and cell engineering strategies, immunotherapies and vaccines to treat cancer, rare disease, autoimmunity and other chronic and infectious illnesses for the benefit of patients, public health, and society.
2026 · 3rd Quarter (July 1 - Sep 30)
ALLIANCE FOR MRNA MEDICINES
Filed by LEAVITT PARTNERS, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- LEAVITT PARTNERS, LLC
- Filing UUID
- c863edd8-2a16-4484-9dca-4a7bd2631960
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.